Page last updated: 2024-11-12

amlodipine nicotinate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

amlodipine nicotinate: salt formulation of amlodipine for the management of angina and hypertension [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10196293
SCHEMBL ID2255622
MeSH IDM0509604

Synonyms (8)

Synonym
amlodipine nicotinate
SCHEMBL2255622
amlodipine nicotinate [who-dd]
3,5-pyridinedicarboxylic acid, 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, 3-pyridinecarboxylate (1:1)
3,5-pyridinedicarboxylic acid, 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-, 3-ethyl 5-methyl ester, 3-pyridinecarboxylate (1:1)
9mk7v6y9c6 ,
616203-96-4
unii-9mk7v6y9c6

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Also, the incidence and severity of adverse events (AEs) and adverse drug reactions (ADRs) were reported."( Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: an 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, ph
Ahn, TH; Chung, N; Kim, SA; Lim, DS; Oh, BH; Park, S; Tahk, SJ; Yang, JY, 2008
)
0.61

Pharmacokinetics

ExcerptReferenceRelevance
" Here, we evaluated the comparative pharmacokinetic and pharmacodynamic characteristics of the nicotinate and besylate forms of amlodipine."( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects.
Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006
)
0.55
" Blood samples for the pharmacokinetic analysis of amlodipine were obtained over the 144-hour period after administration."( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects.
Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006
)
0.55
" After administering a single dose of each formulation, mean AUC0-infinity and Cmax values were 190."( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects.
Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006
)
0.55
"The two amlodipine formulations showed similar pharmacokinetic and pharmacodynamic characteristics and the new amlodipine formulation, amlodipine nicotinate, was found to be equivalent for pharmacokinetics to the currently available amlodipine besylate with respect to the rate and extent of amlodipine absorption."( Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects.
Ha, MC; Kim, JS; Kim, KA; Lee, GH; Lee, OJ; O, MJ; Park, JH; Park, JY; Park, PW; Ryu, JH, 2006
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (33.33)29.6817
2010's4 (66.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.52 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (66.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other2 (33.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]